📊

Executive Summary

ARGX-125 is a preclinical molecule with undisclosed target, planned for Phase 1 initiation in 2026.

ARGX-125

Not disclosed ·

Preclinical (Phase 1 in 2026)

Target: Not disclosed

See Target Biology →

Mechanism of Action

Target Biology

Target not yet disclosed by argenx. Phase 1 initiation planned for 2026.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

Event	Timing	Importance	Key Metrics to Watch	Consensus
Phase 1 initiation	2026	medium	Target disclosure and first-in-human data	—

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy